Granules’ generic for ADHD secures U.S. FDA tentative nod

[ad_1] The U.S. FDA approval further strengthens the U.S. generics portfolio of the Granules’, says the company’s CMD. File | Photo Credit: Reuters Granules India, through a subsidiary, has received U.S. Food and Drug Administration’s (FDA’s) tentative approval for its generic of attention deficit hyperactivity disorder drug Adzenys-XR-ODT. The product, indicated for the treatment of […]

Continue Reading

Dr. Reddy’s to acquire Slayback’s eyedrop rights

[ad_1] Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain rights to New Jersey-based Slayback Pharma’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Slayback Pharma is the first to file an ANDA (abbreviated new drug application) for the private label equivalent for Lumify with the U.S. Food and Drug Administration (USFDA) under Paragraph […]

Continue Reading